PhenomeX Gestion

Gestion contrôle des critères 1/4

Le PDG PhenomeX est Siddhartha Kadia, nommé en Mar2022, a un mandat de 1.58 ans. La rémunération annuelle totale est $ 10.10M, composée du salaire de 5.6% et des bonus 94.4%, y compris les actions et options de la société. détient directement 0.65% des actions de la société, d'une valeur de $ 644.07K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.2 ans et 3.3 ans.

Informations clés

Siddhartha Kadia

Directeur général

US$10.1m

Rémunération totale

Pourcentage du salaire du PDG	5.6%
Durée du mandat du directeur général	1.6yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	1.2yrs
Durée moyenne du mandat des membres du conseil d'administration	3.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

May 16

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Apr 17

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Aug 15

Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development

Jun 09

Berkeley Lights Q1 2021 Earnings Preview

May 10

Analyse de la rémunération des PDG

Comment la rémunération de Siddhartha Kadia a-t-elle évolué par rapport aux bénéfices de PhenomeX?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2023	n/a	n/a	-US$125m
Mar 31 2023	n/a	n/a	-US$100m
Dec 31 2022	US$10m	US$567k	-US$98m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$309k	n/a	-US$72m

Rémunération vs marché: La rémunération totale de Siddhartha ($USD 10.10M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 652.28K ).

Rémunération et revenus: La rémunération de Siddhartha a augmenté alors que l'entreprise n'est pas rentable.

PDG

Siddhartha Kadia (53 yo)

1.6yrs

Titularisation

US$10,096,450

Compensation

Dr. Siddhartha Chandrakant Kadia, Ph D., M.S (Biomedical Engineering) & BE (Electronics and Telecommunication), has been Director at Berkeley Lights, Inc. since September 07, 2021 and serves as its Chief E...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Siddhartha Kadia	CEO & Director	1.6yrs	US$10.10m	0.65% $ 644.1k
Mehul Joshi	CFO & Principal Accounting Officer	1.3yrs	US$3.02m	0.065% $ 64.9k
Scott Chaplin	Chief Legal Officer & Corporate Secretary	1.1yrs	US$1.95m	0.020% $ 19.9k
Eric Hobbs	Executive Vice President of Integrations & Business Transformation	less than a year	US$1.78m	0.24% $ 242.6k
Suzanne Hatcher	Vice President of Communications & Investor Relations	no data	pas de données	pas de données
Lucas Vitale	Chief Human Resources Officer	1.5yrs	pas de données	pas de données
Rolando Brawer	Chief Business Officer	less than a year	pas de données	pas de données

1.2yrs

Durée moyenne de l'emploi

49.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CELL n'est pas considérée comme expérimentée (ancienneté moyenne 1.2 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Siddhartha Kadia	CEO & Director	2.1yrs	US$10.10m	0.65% $ 644.1k
Dan Maydan	Member of Scientific Advisory Board	no data	pas de données	pas de données
Igor Khandros	Co-Founder & Independent Director	12.8yrs	US$225.01k	9.02% $ 9.0m
Elizabeth Nelson	Independent Director	4.1yrs	US$247.01k	0.076% $ 75.8k
Gregory Lucier	Independent Chairman of the Board	3.3yrs	US$370.09k	0.14% $ 135.8k
James E. Rothman	Chairman of Scientific Advisory Board	no data	US$345.01k	0.14% $ 144.0k
Ming Wu	Co-Founder & Member of Scientific Advisory Board	3.3yrs	pas de données	pas de données
John Chiminski	Independent Director	2.4yrs	US$237.51k	0.041% $ 40.8k
Eric Schadt	Member of Scientific Advisory Board	no data	pas de données	pas de données
Deepak Srivastava	Member of Scientific Advisory Board	no data	pas de données	pas de données
Jessica Hopfield	Independent Director	1.8yrs	US$233.01k	0.10% $ 103.4k
Adam Arkin	Member of Scientific Advisory Board	no data	pas de données	pas de données

3.3yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CELL sont considérés comme expérimentés (ancienneté moyenne 3.3 ans).

PhenomeX Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

High number of new directors

Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate Secretary

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Recent updates

Bruker Cellular Analysis, Inc. Files Form 15

Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform

PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Consensus EPS estimates upgraded to US$1.13 loss

Consensus EPS estimates fall by 22%

Price target decreased by 29% to US$4.00

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

New major risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023

PhenomeX Inc. Announces Lifting of the Stay in AbCellera Patent Infringement Case

PhenomeX Inc.(NasdaqGS:CELL) dropped from Russell Small Cap Comp Value Index

PhenomeX Receives a Notice from Nasdaq Regarding Minimum Bid Price Rule

PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling Workflows

Price target decreased by 31% to US$5.67

Consensus revenue estimates decrease by 16%, EPS upgraded

PhenomeX Inc. Launches Beacon Select Optofluidic System with Opto B Discovery Workflows

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Full year 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022

Berkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell Workflow

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2022

Berkeley Lights, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate Secretary

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Consensus revenue estimates fall by 17%

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Full Year 2022

Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer Neoantigen

Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

Berkeley Lights Inc. Announces Mehul Joshi as New Chief Financial Officer

Mehul Joshi joins Berkeley Lights as CFO

Berkeley Lights, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider notifies of intention to sell stock

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$16.80

High number of new directors

Berkeley Lights, Inc., Annual General Meeting, May 26, 2022

Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources Officer

Insider recently bought US$502k worth of stock

Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning Platforms

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Berkeley Lights, Inc. Reiterates Revenue Guidance for Full Year 2022

Price target decreased to US$30.40

Berkeley Lights, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Berkeley Lights, Inc

High number of new directors

Berkeley Lights, Inc. Provides Revenue Guidance for Full Year of 2021 and 2022

Berkeley Lights, Inc. to Showcase its Optofluidic Discovery Technology At 2021 Antibody Engineering & Therapeutics Conference

Berkeley Lights Grows Revenue But Operating Losses Mount

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc

Independent Chairman of the Board recently bought US$500k worth of stock

Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.16 loss in 3Q 2020)

Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions